---
figid: PMC8961612__biomolecules-12-00278-g002
figtitle: Systemic Microvascular Dysfunction in Heart Failure with Preserved Ejection
  Fraction
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC8961612
filename: biomolecules-12-00278-g002.jpg
figlink: /pmc/articles/PMC8961612/figure/biomolecules-12-00278-f002/
number: F2
caption: Interventions targeting MVD in HFpEF. The effects of different pharmacological
  interventions (blue) on the NO-sGC-cGMP-PKG pathway in MVD in HFpEF. ROS causes
  impaired NO bio-availability, subsequently disturbing the downstream signalling.
  The entire pathway offers different targets for therapy. cGMP, Cyclic guanosine
  monophosphate; EC, endothelial cell; Fpassive, passive force; NO, nitric oxide;
  NO2−, nitrite; NP, natriuretic peptides; NPRA, Natriuretic peptide Receptor Type
  A; O2−, superoxide; ONOO−, peroxynitrite; PDE-i, phosphodiesterase inhibitors; PKG,
  protein kinase G; ROS, reactive oxygen species; sGC, soluble guanylate cyclase;
  SGLT2-i, sodium-glucose co-transporter-2 inhibitor; SMC, smooth muscle cell.
papertitle: The Role of Systemic Microvascular Dysfunction in Heart Failure with Preserved
  Ejection Fraction.
reftext: Jerremy Weerts, et al. Biomolecules. 2022 Feb;12(2):278.
year: '2022'
doi: 10.3390/biom12020278
journal_title: Biomolecules
journal_nlm_ta: Biomolecules
publisher_name: MDPI
keywords: heart failure with preserved ejection fraction | microcirculation | microvascular
  dysfunction | endothelial dysfunction
automl_pathway: 0.9485387
figid_alias: PMC8961612__F2
figtype: Figure
redirect_from: /figures/PMC8961612__F2
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8961612__biomolecules-12-00278-g002.html
  '@type': Dataset
  description: Interventions targeting MVD in HFpEF. The effects of different pharmacological
    interventions (blue) on the NO-sGC-cGMP-PKG pathway in MVD in HFpEF. ROS causes
    impaired NO bio-availability, subsequently disturbing the downstream signalling.
    The entire pathway offers different targets for therapy. cGMP, Cyclic guanosine
    monophosphate; EC, endothelial cell; Fpassive, passive force; NO, nitric oxide;
    NO2−, nitrite; NP, natriuretic peptides; NPRA, Natriuretic peptide Receptor Type
    A; O2−, superoxide; ONOO−, peroxynitrite; PDE-i, phosphodiesterase inhibitors;
    PKG, protein kinase G; ROS, reactive oxygen species; sGC, soluble guanylate cyclase;
    SGLT2-i, sodium-glucose co-transporter-2 inhibitor; SMC, smooth muscle cell.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Np
  - Gycalpha99B
  - Pkg21D
  - for
  - dnc
  - fliF
  - ec
  - NPR1
  - MTG1
  - SGCB
  - GUCY1A2
  - GUCY1A1
  - GUCY1B1
  - GUCY1B2
  - PRKG1
  - ALDH7A1
  - PDE2A
  - PDE9A
  - PDE10A
  - PDE11A
  - PDE1A
  - PDE1B
  - PDE1C
  - PDE3A
  - PDE3B
  - PDE4A
  - PDE4B
  - PDE4C
  - PDE4D
  - PDE6A
  - PDE6B
  - PDE6C
  - PDE7A
  - PDE7B
  - PDE8A
  - PDE8B
  - NT5C2
---
